Idorsia Aktie - 19T

Idorsia Ltd (19T) Aktie

Professionelle Tools für Privatanleger.

Premium

Current Price

6,105

( -3,33% )

Gebot

6,075

Fragen

6,135

Volumen

8.953

5,91 Tagesbereich 6,48

0,00 52-Wochen-Bereich 0,00

Handelsende

6,315

Handelsbeginn

6,265

Letzte Trade

6.155

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon

Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon Ad hoc announcement pursuant to Art. 53 LR Senior secured...

Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology

Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology...

New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension

New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant...

Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2026

Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2026 Allschwil, Switzerland – May 6, 2026At today’s...

Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year

Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year Ad hoc announcement pursuant to Art. 53 LR Preparation is...

Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders

Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders Allschwil, Switzerland – April 10, 2026Idorsia Ltd (SIX: IDIA) today...

Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development

Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development Idorsia thanks Alberto Gimona – most recently...

Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder

Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder Ad hoc announcement pursuant to Art. 53...

Idorsia announces the nomination of three candidates for election to the Board of Directors

Idorsia announces the nomination of three candidates for election to the Board of Directors Idorsia nominates three Board Directors with...

Idorsia announces management change

Idorsia announces management change Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 16, 2026Idorsia Ltd (SIX:...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

19T - Frequently Asked Questions (FAQ)

What is the current Idorsia Ltd share price?

The current share price of Idorsia Ltd is 6,105 €

What is the 1 year trading range for Idorsia Ltd share price?

Idorsia Ltd has traded in the range of 0,00 € to 0,00 € during the past year

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Idorsia Ltd (19T)

Idorsia Ltd (19T) Aktie

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

19T Neueste Nachrichten

Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon

Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology

New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension

Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2026

Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year

Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders

Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development

Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder

Idorsia announces the nomination of three candidates for election to the Board of Directors

Idorsia announces management change

19T - Frequently Asked Questions (FAQ)

19T Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Idorsia Ltd (19T)

Idorsia Ltd (19T) Aktie

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

19T Neueste Nachrichten

Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon

Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology

New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension

Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2026

Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year

Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders

Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development

Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder

Idorsia announces the nomination of three candidates for election to the Board of Directors

Idorsia announces management change

19T - Frequently Asked Questions (FAQ)

19T Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich GRATIS und erhalten Sie:

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE